seri
seventeen
hitherto
unknown
anp
analog
bear
e
aliphat
side
chain
modifi
heterocycl
base
cytosin
prepar
straight
approach
olefin
acycl
cross
metathesi
key
synthet
step
novel
compound
evalu
antivir
activ
larg
number
dna
rna
virus
includ
herp
simplex
viru
type
varicella
zoster
viru
felin
herp
viru
human
cytomegaloviru
hepat
c
viru
hcv
among
molecul
compound
show
activ
human
cytomegaloviru
hel
cell
cultur
ec
mm
compound
demonstr
pronounc
antihcv
activ
without
signific
cytotox
mm
elsevi
masson
sa
right
reserv
abbrevi
vzv
varicella
zoster
viru
vv
vaccinia
viru
hsv
herp
simplex
viru
vsv
vesicular
stomat
viru
dna
deoxyribonucl
acid
rna
ribonucl
acid
cc
compound
concentr
afford
inhibit
cell
growth
ec
compound
concentr
afford
inhibit
viral
cytopath
mcc
minimum
cytotox
concentr
requir
afford
microscop
detect
alter
cell
morpholog
mdck
madinedarbi
canin
kidney
discoveri
e
de
clercq
broadspectrum
antivir
activ
hpmpa
phosphonomethoxi
propyl
adenin
pmea
phosphonom
thoxi
ethyl
adenin
led
new
famili
nucleotid
design
acycl
nucleosid
phosphon
anp
anp
nucleotid
analog
character
presenc
phosphon
group
link
pyrimidin
purin
base
aliphat
linker
three
approv
drug
treatment
severefat
infecti
diseas
repres
three
differ
type
anp
hpmp
deriv
phosphonomethoxi
propyl
cytosin
hpmpc
cidofovir
vistid
approv
treatment
cytomegaloviru
cmv
retin
aid
patient
ii
pme
deriv
pmea
adefovir
oral
prodrug
form
adefovir
dipivoxil
hepsera
treatment
hepat
b
viru
infect
iii
pmp
deriv
pmpa
tenofovir
oral
prodrug
form
tenofovir
disoproxil
fumar
viread
use
treatment
hiv
infect
aid
hepat
b
viru
data
appear
small
chemic
alter
acycl
sidechain
lead
mark
differ
antivir
activ
spectrum
activ
acycl
nucleosid
phosphon
variou
class
viral
agent
thu
synthesi
biolog
evalu
larg
panel
anp
systemat
investig
potenti
antivir
compound
search
antivir
compound
synthes
new
class
acycl
nucleosid
phosphon
base
base
motif
oxygen
heteroatom
replac
doubl
bond
tran
stereochemistri
shown
modif
allow
mimicri
threedimension
geometri
provid
backbon
pmea
pmpa
cdv
maintain
electron
contribut
similar
brought
oxygen
atom
sever
new
deriv
effici
activ
human
thymidyl
kinas
htmpk
best
substrat
convert
bi
pivaloyloxymethyl
ester
phosphon
prodrug
found
activ
sever
herp
virus
cell
cultur
basi
find
interest
design
synthes
hitherto
unknown
anp
analog
bear
biolabil
phosphon
e
aliphat
sidechain
seri
modifi
heterobas
select
literatur
lead
nucleobas
antivir
properti
cytosin
cytosin
fig
chemic
synthesi
point
view
strategi
base
olefin
cross
metathesi
develop
obtain
larg
librari
e
yl
pyrimidin
nucleosid
first
turn
attent
synthesi
cytosin
deriv
cytosin
modifi
nucleosid
form
prolif
famili
antitumor
antivir
agent
could
except
even
ruthenium
carben
complex
grubbsenolan
catalyst
gener
less
affect
free
amin
nitrogencontain
group
grubb
gener
catalyst
crossmetathesi
reaction
unprotect
n
crotyl
cytosin
bi
pom
allylphosphon
fail
scheme
success
crossmetathesi
occur
protect
n
cytosin
b
thu
cytosin
convert
n
bisboc
cytosin
deriv
b
respect
nperacyl
follow
subsequ
regioselect
n
deprotect
satur
solut
nahco
methanol
crotyl
n
posit
b
use
cs
co
crotyl
bromid
afford
desir
compound
compound
b
engag
olefin
cross
metathesi
reaction
bi
pom
allylphosphon
use
mol
nhc
ru
chr
nolan
catalyst
cl
pci
ime
ru
chph
dri
ch
cl
reflux
afford
e
n
pom
butenyl
bisboccytosin
b
moder
yield
r
h
r
f
remov
boc
group
requir
oftentim
harsh
condit
eg
trifluoroacet
acid
trimethylsilyl
iodid
hydrochlor
acid
ethyl
acet
potassium
carbon
etc
compat
pom
moieti
howev
hwu
et
al
report
effici
milder
select
boc
deprotect
neutral
condit
use
ceric
ammonium
nitrat
consist
stabil
phosphon
biolabil
group
thu
protect
anp
b
react
catalyt
amount
ceric
ammonium
nitrat
mmol
ch
cnemeoh
give
expect
compound
b
respect
moder
yield
observ
remov
pom
moieti
scheme
turn
attent
synthesi
pyrazinecarboxamid
deriv
sinc
among
modifi
nucleobas
seri
pyrazinecarboxamid
deriv
includ
favipiravir
develop
furuta
et
al
demonstr
good
activ
variou
rna
viral
infect
first
attempt
struggl
introduc
pyrazin
moieti
direct
nalkyl
correspond
e
yl
bromid
presenc
k
co
anhydr
dmf
pathway
unfortun
bi
pom
phosphon
result
undesir
bromin
elimin
obtain
scheme
thu
decid
reach
pyrazin
phosphon
analog
follow
strategi
develop
cytosin
deriv
pathway
b
start
n
bisboccarboxamid
obtain
yield
via
two
step
crotylationnbocprotect
next
n
bi
boc
carboxamid
ch
cl
treat
presenc
bi
pom
allylphosphon
nhc
ru
chr
nolan
catalyst
give
desir
product
yield
obtain
carboxamid
first
appli
previou
describ
method
use
ceric
ammonium
nitrat
ch
cnemeoh
surprisingli
methylest
isol
major
compound
yield
think
presenc
undesir
product
due
use
methanol
cosolv
prepar
desir
amid
achiev
ch
cn
use
ceric
ammonium
nitrat
yield
base
result
extend
approach
format
ribavirin
analog
bear
deriv
start
protect
nitrogen
provid
compound
quantit
yield
directli
use
next
step
attempt
select
boc
deprotect
n
posit
altern
decid
success
alkyl
n
posit
presenc
crotyl
bromid
cs
co
follow
protect
free
nitrogen
dri
thf
presenc
boc
dmap
room
temperatur
give
desir
triazol
two
step
scheme
n
subject
olefin
cross
metathesi
reaction
bi
pom
allylphosphon
ch
cl
obtain
desir
compound
yield
bisboc
group
cleav
accord
previou
procedur
treatment
mixtur
ch
cnemeoh
give
free
anp
analog
yield
scheme
complet
investig
elabor
small
librari
anp
prodrug
form
bear
substitut
moieti
triazol
deriv
obtain
use
cu
catalyz
azideealkyn
cycloaddit
cuaac
use
select
alkyn
phosphon
azid
introduct
azid
group
could
easili
perform
key
intermedi
previous
describ
olefin
cross
metathesi
bi
pom
allylphosphon
e
catalyz
catalyst
afford
e
pom
allylphosphon
yield
introduct
azido
sodium
azid
dmsoethfeh
afford
e
pom
allylphosphon
yield
scheme
among
modif
base
moieti
carboxyl
acid
unavoid
function
first
attempt
follow
previous
describ
method
c
presenc
propiol
acid
microwav
irradi
observ
format
isol
unexpect
decarboxyl
product
yield
circumv
decarboxyl
hall
et
al
report
boron
acid
catalysi
bac
activ
carboxyl
acid
lead
classic
dipolar
cycloaddit
sever
azid
obtain
desir
e
acid
methylbi
pom
deriv
select
bac
azideealkyn
cycloaddit
convert
yield
presenc
acid
room
temperatur
final
coppercatalyz
azidealkyn
cycloaddit
cuaac
afford
chemoselect
complet
regioselect
permit
synthesi
number
anp
analog
tabl
first
seri
bi
pom
congen
bear
substitut
phenylacetylen
moieti
chosen
apolar
bulki
substitu
obtain
cuaac
reaction
cu
cuso
catalyst
presenc
substitut
phenylacetylen
ethynylthiophen
nonaromat
alkyn
moder
good
yield
rang
tabl
entri
room
temperatur
method
reaction
synthon
room
temperatur
led
trace
amount
expect
product
howev
isol
cycloaddit
carri
c
tabl
entri
method
b
afford
compound
yield
respect
howev
alkyn
list
tabl
entri
allow
format
triazol
product
thermal
condit
microwav
heat
known
power
tool
produc
varieti
nucleosid
product
follow
previou
work
microwav
irradi
allow
obtain
moder
yield
desir
anp
yield
respect
tabl
entri
method
c
titl
bi
pom
e
acycl
nucleosid
subject
vitro
antivir
screen
use
wide
spectrum
virus
mdkc
cell
cultur
antiinfluenza
viru
activ
vero
cell
cultur
antivir
activ
parainfluenza
shown
compound
show
activ
ec
mm
strain
observ
cytotox
mm
tabl
compound
also
evalu
inhibit
hepat
c
viru
hcv
subgenom
hcv
replicon
system
huh
cell
cytotox
test
perform
pbmc
human
lymphoblastoid
cem
vero
cell
data
antihcv
activ
antihiv
activ
cytox
shown
tabl
mani
compound
found
moder
cytotox
must
consid
interpret
antihcv
data
compound
demonstr
antihcv
activ
without
signific
cytotox
mm
molecul
show
pronounc
inhibit
mm
compound
concentr
close
cytostat
activ
effici
synthes
seri
seventeen
hitherto
unknown
anp
analog
bear
aliphat
side
chain
seri
modifi
heterocycl
base
cytosin
ide
evalu
antivir
activ
among
test
molecul
compound
show
activ
human
cytomegaloviru
ec
mm
strain
subtox
concentr
observ
cytotox
mm
compound
demonstr
pronounc
antihcv
activ
mm
without
signific
cytotox
mm
structur
optim
e
aliphat
side
chain
heterocycl
well
way
alongsid
detail
biolog
test
activ
compound
aim
improv
antivir
potenc
commerci
avail
chemic
reagent
grade
use
receiv
solvent
dri
follow
standard
procedur
reaction
monitor
thin
layer
chromatographi
tlc
analysi
use
silica
gel
plate
kieselgel
e
merck
column
chromatographi
perform
silica
gel
mm
e
merck
h
p
c
nmr
spectra
record
varian
inova
uniti
spectromet
mhz
methanol
cdcl
shift
valu
part
per
million
rel
sime
intern
refer
high
resolut
mass
spectra
hrm
perform
bruker
maxi
mass
spectromet
de
recherch
icoacbm
fr
platform
physicochem
data
agreement
report
inform
ca
number
stir
suspens
cytosin
argon
atmospher
mg
mmol
equiv
dri
thf
ml
dmap
mg
mmol
equiv
boc
g
mmol
equiv
ad
h
stir
room
temperatur
mixtur
dilut
etoac
extract
ml
etoac
combin
organ
layer
wash
brine
dri
mgso
concentr
vacuo
result
triboccytosin
use
next
step
without
purif
solut
triboccytosin
methanol
ml
ad
satur
nahco
aq
solut
ml
room
temperatur
stir
h
c
confirm
complet
consumpt
substrat
examin
tlc
develop
petroleum
ethereetoac
remov
methanol
vacuo
mixtur
dilut
etoac
ml
quench
water
ml
final
extract
etoac
ml
combin
organ
layer
wash
brine
dri
mgso
concentr
vacuo
residu
purifi
silica
gel
column
chromatographi
petroleum
ether
etoac
give
mg
white
solid
analog
manner
prepar
prepar
mg
white
solid
solut
mg
mmol
equiv
dri
dmf
ml
ad
cs
co
mg
mmol
equiv
crotyl
bromid
mg
mmol
equiv
room
temperatur
stir
argon
atmospher
h
result
mixtur
dilut
etoac
ml
quench
water
extract
etoac
combin
organ
layer
wash
brine
dri
mgso
concentr
vacuo
residu
purifi
silica
gel
column
chromatographi
petroleum
ethereetoac
give
mixtur
z
minor
e
major
n
n
bisbocn
crotylcytosin
mg
yellow
oil
similar
manner
describ
solut
mg
mmol
ml
ch
cnemeoh
treat
ceric
ammonium
nitrat
mg
mmol
give
e
n
bi
pom
butenyl
mg
colorless
oil
solut
bi
pom
allylphosphon
mmol
equiv
ml
dri
ch
cl
ad
e
g
mmol
equiv
nhc
ru
chr
nolan
catalyst
mg
mmol
equiv
h
stir
c
argon
atmospher
volatil
evapor
residu
purifi
silica
gel
chromatographi
elut
petroleum
ethereetoac
give
e
pom
mg
brown
oil
similar
manner
describ
solut
mg
mmol
dri
dmf
ml
treat
cs
co
mg
mmol
crotyl
bromid
mg
mmol
h
c
give
crude
mixtur
ez
n
evapor
volatil
rapid
silica
gel
chromatographi
residu
mg
treat
dmap
mg
mmol
boc
mg
mmol
dri
thf
ml
give
n
mg
colorless
oil
similar
manner
describ
solut
bi
pom
allylphosphon
mg
mmol
n
nbisboccarboxamid
mg
mmol
dri
ch
cl
ml
treat
nhc
ru
chr
nolan
catalyst
mg
mmol
give
mg
yellow
oil
solut
mg
mmol
equiv
dri
dmf
ml
ad
cs
co
mg
mmol
equiv
crotyl
bromid
mg
mmol
equiv
reaction
solut
stir
room
temperatur
argon
atmospher
h
warm
c
h
concentr
dryness
vacuo
residu
subject
silica
gel
chromatographi
ch
cl
e
meoh
employ
next
step
without
purif
residu
mg
suspend
thf
ml
dmap
mg
mmol
equiv
boc
g
mmol
equiv
ad
argon
atmospher
solut
stir
h
room
temperatur
mixtur
dilut
etoac
extract
etoac
combin
organ
layer
wash
brine
dri
mgso
concentr
vacuo
residu
purifi
silica
gel
column
chromatographi
elut
petroleum
ethereetoac
give
mixtur
z
minor
e
major
n
mg
colorless
oil
similar
manner
describ
solut
e
n
pom
butenyl
mg
mmol
ml
ch
cnemeoh
treat
ceric
ammonium
nitrat
mg
mmol
give
e
n
bi
pom
butenyl
mg
colorless
oil
solut
e
pom
mg
mmol
equiv
mixtur
dmso
ml
thf
ml
h
ml
ad
sodium
azid
mg
mmol
equiv
h
stir
room
temperatur
mixtur
dilut
etoac
water
extract
etoac
combin
organ
layer
wash
brine
dri
mgso
concentr
vacuo
residu
purifi
silica
gel
column
chromatographi
elut
petroleum
ether
etoac
give
e
pom
procedur
solut
alkyn
equiv
e
pom
mmol
equiv
tbuohh
ratio
ml
ad
cu
powder
mg
mmol
equiv
cuso
mg
mmol
equiv
result
suspens
stir
h
room
temperatur
crude
mixtur
dilut
etoac
ml
directli
transfer
prepar
thin
layer
silica
plate
give
e
bi
pom
enylphosphon
procedur
b
follow
procedur
describ
result
suspens
stir
h
c
procedur
c
similar
procedur
mixtur
stir
h
microwav
condit
c
titl
compound
prepar
procedur
c
give
colorless
oil
titl
compound
prepar
procedur
give
yellow
oil
titl
compound
prepar
typic
procedur
c
give
colorless
oil
titl
compound
prepar
typic
procedur
c
give
yellow
oil
viral
cytopath
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopathogen
viral
plaqu
vzv
format
minim
cytotox
concentr
mcc
compound
defin
compound
concentr
caus
microscop
visibl
alter
cell
morpholog
altern
cytostat
activ
test
compound
measur
base
inhibit
cell
growth
hel
cell
seed
rate
cellswel
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
day
incub
c
cell
number
determin
coulter
counter
cytostat
concentr
calcul
cc
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
methodolog
antihiv
assay
follow
human
cem
cell
cm
cell
infect
ccid
hiv
iii
b
rod
ml
seed
ml
well
microtit
plate
contain
appropri
dilut
test
compound
day
incub
c
hivinduc
cem
giant
cell
format
examin
microscop
hepat
c
antivir
activ
evalu
previous
describ
huh
clone
b
cell
contain
hcv
replicon
rna
seed
plate
cellswel
compound
test
mm
triplic
immedi
seed
follow
five
day
incub
c
co
total
cellular
rna
isol
use
well
extract
kit
qiagen
replicon
rna
intern
control
taqman
rrna
control
reagent
appli
biosystem
amplifi
singl
step
multiplex
real
time
rtpcr
assay
antivir
effect
compound
calcul
subtract
threshold
rtpcr
cycl
test
compound
threshold
rtpcr
cycl
nodrug
control
dcthcv
dct
equal
reduct
equal
less
start
materi
replicon
rna
level
cytotox
compound
also
calcul
use
dct
rrna
valu
cmec
use
control
test
mm
determin
valu
dct
valu
first
convert
fraction
start
materi
use
calcul
inhibit
